{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Systemic+Lupus+Erythematosis&page=2", "query": { "condition": "Systemic Lupus Erythematosis", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 463, "total_pages": 47, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Systemic+Lupus+Erythematosis&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Systemic+Lupus+Erythematosis&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T05:00:32.728Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00519454", "title": "Estrogen and Gender Biased Autoimmunity", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "Peripheral lab draws", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "The Center for Rheumatic Disease, Allergy, & Immunology", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "18 Years to 50 Years · Female only" }, "enrollment_count": 75, "start_date": "2005-04", "completion_date": "2013-12", "has_results": false, "last_update_posted_date": "2010-09-08", "last_synced_at": "2026-10-04T05:00:32.728Z", "location_count": 1, "location_summary": "Kansas City, Missouri", "locations": [ { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00519454" }, { "nct_id": "NCT03724916", "title": "A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Systemic Lupus Erythematosus", "Lupus Erythematosus, Systemic" ], "interventions": [ { "name": "TAK-079", "type": "DRUG" }, { "name": "TAK-079 Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 23, "start_date": "2018-11-26", "completion_date": "2021-11-04", "has_results": true, "last_update_posted_date": "2024-03-29", "last_synced_at": "2026-10-04T05:00:32.728Z", "location_count": 19, "location_summary": "Anniston, Alabama • Birmingham, Alabama • La Jolla, California + 15 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Poway", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03724916" }, { "nct_id": "NCT06927219", "title": "Research Accelerated by You Lupus Registry", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Systemic Lupus Erythematosus (SLE)", "Lupus Nephritis (LN)", "Cutaneous Lupus Erythematosus (CLE)" ], "interventions": [], "intervention_types": [], "sponsor": "Lupus Foundation of America", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 10000, "start_date": "2020-10-01", "completion_date": "2050-12-31", "has_results": false, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-10-04T05:00:32.728Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06927219" }, { "nct_id": "NCT01716312", "title": "Omalizumab for Lupus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Systemic Lupus Erthematosus", "Sjogren's Syndrome" ], "interventions": [ { "name": "Omalizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 17, "start_date": "2014-01-08", "completion_date": "2017-08-24", "has_results": false, "last_update_posted_date": "2022-04-20", "last_synced_at": "2026-10-04T05:00:32.728Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01716312" }, { "nct_id": "NCT07260877", "title": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cutaneous Lupus Erythematosus (CLE)", "Systemic Lupus Erythematosus", "SLE", "SLE (Systemic Lupus)", "CLE" ], "interventions": [ { "name": "VENT-03", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ventus Therapeutics U.S., Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 24, "start_date": "2025-12-03", "completion_date": "2026-09", "has_results": false, "last_update_posted_date": "2026-07-27", "last_synced_at": "2026-10-04T05:00:32.728Z", "location_count": 13, "location_summary": "Beverly Hills, California • Clearwater, Florida • DeBary, Florida + 10 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Clearwater", "state": "Florida" }, { "city": "DeBary", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT07260877" }, { "nct_id": "NCT06804057", "title": "CorEvitas Systemic Lupus Erythematosus (SLE) Drug Safety and Effectiveness Registry", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "Blood Collection", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "CorEvitas", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1000, "start_date": "2024-09-26", "completion_date": "2099-12-31", "has_results": false, "last_update_posted_date": "2026-02-06", "last_synced_at": "2026-10-04T05:00:32.728Z", "location_count": 1, "location_summary": "Waltham, Massachusetts", "locations": [ { "city": "Waltham", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06804057" }, { "nct_id": "NCT00071487", "title": "Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lupus Erythematosus, Systemic" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Belimumab 1 mg/kg", "type": "DRUG" }, { "name": "Belimumab 4 mg/kg", "type": "DRUG" }, { "name": "Belimumab 10 mg/kg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Human Genome Sciences Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 449, "start_date": "2003-10", "completion_date": "2006-06", "has_results": true, "last_update_posted_date": "2013-08-07", "last_synced_at": "2026-10-04T05:00:32.728Z", "location_count": 60, "location_summary": "Birmingham, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 52 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00071487" }, { "nct_id": "NCT07138898", "title": "Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatic Disease" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" }, { "name": "Sulfasalazine", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Leflunomide", "type": "DRUG" }, { "name": "Azathioprine", "type": "DRUG" }, { "name": "Mycophenolate", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Golimumab", "type": "DRUG" }, { "name": "Certolizumab", "type": "DRUG" }, { "name": "Infliximab", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Belimumab", "type": "BIOLOGICAL" }, { "name": "Tocilizumab", "type": "BIOLOGICAL" }, { "name": "Anakinra", "type": "BIOLOGICAL" }, { "name": "Canakinumab", "type": "BIOLOGICAL" }, { "name": "Abatacept", "type": "BIOLOGICAL" }, { "name": "Secukinumab", "type": "BIOLOGICAL" }, { "name": "Ixekizumab", "type": "BIOLOGICAL" }, { "name": "Bimekizumab", "type": "BIOLOGICAL" }, { "name": "Ustekinumab", "type": "BIOLOGICAL" }, { "name": "Guselkumab", "type": "BIOLOGICAL" }, { "name": "Risankizumab", "type": "BIOLOGICAL" }, { "name": "Tofacitinib", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2025-12-12", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-10-04T05:00:32.728Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07138898" }, { "nct_id": "NCT00111306", "title": "Study of Epratuzumab in Systemic Lupus Erythematosus", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "epratuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 510, "start_date": "2005-06", "completion_date": "2007-03", "has_results": false, "last_update_posted_date": "2011-11-08", "last_synced_at": "2026-10-04T05:00:32.728Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Upland", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00111306" }, { "nct_id": "NCT07430306", "title": "A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "Anifrolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 245, "start_date": "2026-04-13", "completion_date": "2029-01-26", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-04T05:00:32.728Z", "location_count": 31, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 24 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fontana", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07430306" } ] }